The U.S. Supreme Court on Monday declined to hear a Johnson & Johnson subsidiary’s appeal of a $124 million penalty imposed by South Carolina after a jury found the drugmaker had improperly marketed the anti-psychotic drug Risperdal and concealed its …
South Carolina’s highest court further reduced the penalty against a Johnson & Johnson subsidiary accused of deceptive marketing of an anti-psychotic drug. The decision was to substitute the same verdict the court reached in February in order to correct a …
South Carolina’s Supreme Court ordered Johnson & Johnson to pay a penalty of $136 million, upholding a jury’s finding that the drugmaker’s Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks. A trial court had earlier …
